PFIZER

Under the new rules, there will be a three-year limit on foreign companies bulking up on U.S. assets to avoid ownership requirements for a later inversions deal.

According to Americans for Tax Fairness, the deal would allow the U.S. pharma giant to "permanently dodge" taxes owed on about $148 billion in overseas profits.

The most important economic variable of 2016 might be whether American consumers are strong enough to withstand the cold winds blowing in from abroad.

Developing a vaccine against the mosquito-borne virus could take years, researchers have said.

The New York-based pharmaceutical company reported a better-than-expected 7 percent rise in quarterly revenue Tuesday.

The healthcare conglomerate said Tuesday the restructuring would affect its orthopedics, surgery and cardiovascular businesses.

The company raised prices, by as much as 20 percent for some drugs, on Jan. 1.

The past year saw deals worth nearly $4.3 trillion — significantly above the previous peak, before the financial crisis, according to a Thursday report.

The deals, which include an upfront payment of $350 million, will help the British drugmaker compete with its American rival Gilead Sciences.

The British drugmaker has shown interest in Acerta's anti cancer treatments, particularly an experimental drug called Acalabrutinib.

Global M&A activity rose as companies looked for tax havens and took advantage of cheap interest rates, the Wall Street Journal reported, citing a research report.

Japan stocks are little changed after a holiday while Australian shares fell, dragged down by falling metal prices.

The total value of mergers and acquisitions has surpassed the previous record set in 2007, with more than $3.8 trillion in global transactions.

In the biggest-ever healthcare merger, Pfizer will move its headquarters to Ireland, freeing up billions of dollars in deferred U.S. tax liabilities.

The pharma companies on Monday confirmed a merger, valued at about $160 billion, that would create the world’s largest drugmaker.

Pfizer CEO Ian Read will lead the combined company, while Allergan CEO Brent Saunders will have another very senior role, sources said.

The U.S. Treasury Department aims to prevent companies from moving abroad to avoid taxes. But big corporations in the midst of inversions aren't blinking.

Pfizer and Allergan said last week that they were in friendly merger talks to create what would be the world's biggest drug company.

Deals announced in 2015 in the pharmaceuticals sector are on track to outpace their record-breaking value from 2014.

The process is at an early stage and may not yield an agreement, according to the Wall Street Journal. However, if the deal materializes, it would create a $330 billion company.

Industries that Clinton cited as enemies have supported her campaigns and family foundation.